Acadia Sells Priority Review Voucher for $150 Million Amid FDA Program Phase-Out

Acadia Pharmaceuticals successfully secured $150 million from the sale of a priority review voucher, a sum that ranks on the higher end for such vouchers. Despite this lucrative deal, Acadia will retain only two-thirds of the proceeds, as the remainder is allocated to Neuren Pharmaceuticals, the original developer of Daybue, a treatment for Rett syndrome, which accompanied the voucher's issuance by the FDA[1][2]. This financial maneuver is strategically positioned amid the FDA's impending phase-out of the rare pediatric disease voucher program, a factor contributing to the voucher's elevated market value. Acadia plans to channel these funds into bolstering commercial operations, delving into further business prospects, and advancing research on central nervous system diseases[1][2].